- Details
- Description
-
Packaging Size120tabs
-
Strength60mg
-
CompositonApalutamide
-
TreatmentProstate Cancer
-
Formtablet
-
BrandAPADX
-
Quantity Unit60mg*120t/bottle
-
ManufacturerBIGBEAR Pharma,Laos PDR
About Apalutamide
Apalutamide is a nonsteroidal antiandrogen medication used for the treatment of prostate cancer. It is an androgen receptor inhibitor.
Prostate Cancer
Indicated for metastatic castration-sensitive prostate cancer (mCSPC) or nonmetastatic, castration-resistant prostate cancer (nmCRPC)
240 mg PO qDay
Dosage Modifications
Grade ≥3 toxicity or intolerable adverse effect
- Permanently discontinue therapy for severe interstitial lung disease/pneumonitis or if no other potential causes of ILD/pneumonitis are identified, or confirmed SCARs, or for other Grade 4 skin reactions
- For other adverse reactions when symptoms improve to Grade ≤1 or original grade, THEN
- Resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted
Grade 3-4 cerebrovascular and ischemic cardiovascular events
- Consider permanent discontinuation
Confirmed SCARS or Grade 4 skin reactions
- Permanently discontinue for confirmed severe cutaneous adverse reactions (SCARs) or other grade 4 skin reactions
Renal impairment
- Mild-to-moderate (eGFR 30-89 mL/min/1.73 m2): No clinical significant difference in pharmacokinetics
- Severe (eGFR ≤30 mL/min/1.73 m2): Pharmacokinetics unknown
Hepatic impairment
- Mild-to-moderate (Child-Pugh A or B): No clinical significant difference in pharmacokinetics
- Severe (Child-Pugh C): Pharmacokinetics unknown
